Latest market price
373.00
+6.84+1.87%
BIOQT61Bio-Rad Laboratories, Inc.·NYSE
373.00+1.87%
Earnings
Up 1.9% — Earnings due 2026-11-04 — pre-report positioning.
Medium confidence
TA
Loading chart...
Screen all →
Snapshot
Index—P/E44.38EPS (ttm)8.25Insider Own8.88%Shs Outstand26.74MPerf Week-1.68%
Market Cap9.79BForward P/E35.74EPS next Y10.25Insider Trans-0.02%Shs Float17.85MPerf Month-0.81%
Enterprise Value9.38BPEG4.68EPS next Q2.23Short Float6.15%Perf Quarter10.00%
Income222.00MP/S3.78EPS this Y-3.63%Short Ratio4.01Perf Half Y42.00%
Sales2.59BP/B1.36EPS next Y5.10%ROA2.17%Short Interest1.10MPerf YTD20.85%
Book/sh268.31P/C6.05EPS next 5Y9.49%ROE3.15%52W High396.23 -5.86%Perf Year20.21%
Cash/sh60.55P/FCF27.73EPS past 3/5Y— -26.07%ROIC1.54%52W Low236.73 57.56%Perf 3Y25.60%
Dividend Est.—EV/EBITDA18.24Sales past 3/5Y-2.68% 0.29%Gross Margin51.90%Volatility3.42% 3.37%Perf 5Y-52.48%
Dividend TTM—EV/Sales3.62EPS Y/Y TTM-29.67%Oper. Margin9.08%ATR (14)12.06Perf 10Y124.54%
Dividend Ex-Date—Quick Ratio2.33Sales Y/Y TTM1.37%Profit Margin8.59%RSI (14)47.32Recom2.36
Dividend Gr. 3/5Y—Current Ratio3.14EPS Q/Q0.38%SMA20-0.16%Beta1.05Target Price350.00
Payout22.03%Debt/Eq0.17Sales Q/Q-0.15%SMA50-2.23%Rel Volume0.83Prev Close366.16
Employees7,450LT Debt/Eq0.11EarningsNov 04SMA20016.75%Avg Volume253.73KPrice373.00
IPO DateFeb 27, 1980Option/ShortYes / YesEPS/Sales Surpr.49.92% 4.33%Net Debt/EBITDA-0.81Volume211,830Change1.87%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-07-26ReiteratedRBC CapitalOutperform$370 → $390
Aug-05-26ReiteratedRBC CapitalOutperform$320 → $370
May-25-26ReiteratedWells FargoEqual Weight$290 → $310
May-14-26ResumedRBC CapitalOutperform$565 → $320
May-01-26ReiteratedWells FargoEqual Weight$320 → $290
Apr-07-26DowngradeCitigroupBuy → Neutral
Feb-16-26ReiteratedWells FargoEqual Weight$340 → $320
Feb-13-26ReiteratedUBSBuy$350 → $335
Oct-30-25ReiteratedWells FargoEqual Weight$340
Oct-01-24UpgradeCitigroupNeutral → Buy$400
Latest News· Times ET
Today
Oct-29-26
Oct-28-26
Oct-27-26
Oct-26-26
Oct-26-2612:10PM
Oct-22-26
Oct-16-26
Oct-14-26
Oct-13-26
Oct-07-26
Oct-06-26
Oct-05-26
Sep-29-26
Company

Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue2,5892,5832,5672,671—————
Cost of Goods Sold Incl. D&A1,2461,2401,1881,244—————
Gross Profit1,3431,3441,3791,427—————
Selling, General and Administrative Excl. Other848820814842—————
Research and Development261257296247—————
Other Operating Expense-1100—————
Operating Income235271269338—————
Interest Expense36494949—————
Unusual Expense
—————————
Non-Operating Income (Expense)152774-2,563-1,138—————
Net Income Before Taxes350996-2,342-850—————
Income Taxes128236-498-213—————
Consolidated Net Income222760-1,844-637—————
Net Income From Continuing Operations222760-1,844-637—————
Net Income222760-1,844-637—————
EPS (Recurring)8.3327.87-65.36-21.82—————
EPS (Basic, Before Extraordinaries)8.3327.87-65.36-21.82—————
EPS (Diluted)8.2527.87-65.36-21.82—————
EBITDA5141,210-2,142-655—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio45.2110.87———————
Price To Sales Ratio3.893.173.583.51—————
Gross Margin51.8752.0353.7253.43—————
Operating Margin9.0810.4910.4812.65—————
Net Margin8.5729.42-71.83-23.85—————
Shares Outstanding27272829—————
Market Capitalization10,0718,1819,1989,364—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$412.63$364.33$316.02$267.72$219.42● Close Price0.00K53.57K107.14K160.72K214.29KUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
DiVincenzo Jonathan P.President & COOOct 24 '26Option Exercise0.001,86903,832Oct 27
EVRAN SEDATEVP, Global Supply ChainOct 20 '26Option Exercise0.001,04404,647Oct 22
SCHWARTZ NORMAN DChairman & CEOSep 06 '26Option Exercise0.003,4550450,873Sep 09
ENLOE COURTNEY CEVP, General Counsel & SecSep 06 '26Option Exercise0.0076801,957Sep 09
BARRY JAMESEVP, President, LSGSep 06 '26Option Exercise0.001,05602,495Sep 09
Allison SchwartzDirectorSep 06 '26Option Exercise0.009201,768Sep 09
EVRAN SEDATEVP, Global Supply ChainSep 06 '26Option Exercise0.0086403,880Sep 09
ENGELHARDT EVA ANETTEEVP, President, CDGSep 06 '26Option Exercise0.001,15202,313Sep 09
Lakkaraju Roop KalyanEVP, Chief Financial OfficerSep 06 '26Option Exercise0.001,53604,933Sep 09
Allison SchwartzDirectorSep 05 '26Option Exercise0.0022801,758Sep 09
BARRY JAMESEVP, President, LSGSep 05 '26Option Exercise0.001,02701,808Sep 09
EVRAN SEDATEVP, Global Supply ChainSep 05 '26Option Exercise0.001,02703,345Sep 09
ENGELHARDT EVA ANETTEEVP, President, CDGSep 05 '26Option Exercise0.001,02701,530Sep 09
DiVincenzo Jonathan P.President & COOSep 05 '26Option Exercise0.001,71202,631Sep 09
ENLOE COURTNEY CEVP, General Counsel & SecSep 05 '26Option Exercise0.0068501,435Sep 09
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.